Liège, Belgium 18 April 2017 – Mithra Pharmaceuticals is pleased to announce the publication of its 2016 Annual Report and the invitation for its Ordinary General Shareholders’ meeting.
The Annual Report which outlines Mithra’s achievements in 2016 includes the following information:
- Overview of Mithra’s R&D pipeline and letter to shareholders;
- Highlights of Mithra’s strategy and outlook for 2017;
- Corporate governance section;
- Financial statements and notes.
François Fornieri, CEO Mithra Pharmaceuticals: “During 2016 we made substantial progress on the key programs that we believe will deliver Mithra’s long-term international growth as a transformational leader in women’s health. We look forward to building on this progress in the year ahead as we move closer to commercializing Estelle® and to selecting a suitable partner to further develop Donesta®. We also anticipate filing for marketing approval for our vaginal contraceptive, Myring™, in both Europe and the US in 2017.”
Mithra releases its Annual Report in English and French. In case of interpretation differences, the English version will prevail. The report is available in English and French and can be downloaded on the website investors.mithra.com as a PDF file.
Ordinary General Shareholders’ meeting
The Ordinary General Shareholders’ meeting of Mithra Pharmaceuticals will be held on 18th May 2017 at 5:00 PM (CEST) in Liège (Belgium). Mithra Pharmaceuticals is pleased to invite its shareholders. The notice for the Ordinary General Shareholder’s meeting including a description of the formalities to participate in the Meeting is available on the website investors.mithra.com.